Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading on Wednesday. Stock investors bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the typical volume of 53 put options.

Maravai LifeSciences Trading Down 1.6 %

NASDAQ:MRVI opened at $7.61 on Friday. The company has a current ratio of 8.00, a quick ratio of 7.41 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $1.91 billion, a PE ratio of -8.46 and a beta of 0.01. The firm’s 50 day moving average is $7.52 and its 200 day moving average is $6.77. Maravai LifeSciences has a 12 month low of $4.52 and a 12 month high of $16.62.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $74.14 million during the quarter, compared to the consensus estimate of $62.99 million. Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. Sell-side analysts expect that Maravai LifeSciences will post -0.15 earnings per share for the current year.

Analyst Ratings Changes

MRVI has been the subject of a number of analyst reports. Craig Hallum initiated coverage on Maravai LifeSciences in a research note on Wednesday, April 10th. They set a “buy” rating and a $15.00 price target for the company. Stifel Nicolaus dropped their target price on shares of Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, February 23rd. Finally, Royal Bank of Canada lifted their target price on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, February 23rd. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.56.

Institutional Investors Weigh In On Maravai LifeSciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Zions Bancorporation N.A. bought a new stake in Maravai LifeSciences during the 1st quarter valued at $28,000. Gladius Capital Management LP bought a new stake in Maravai LifeSciences during the 4th quarter valued at $30,000. Meeder Asset Management Inc. bought a new stake in Maravai LifeSciences during the 1st quarter valued at $31,000. China Universal Asset Management Co. Ltd. raised its holdings in Maravai LifeSciences by 96.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company’s stock valued at $34,000 after acquiring an additional 1,662 shares during the period. Finally, Signaturefd LLC raised its holdings in Maravai LifeSciences by 99.9% during the 3rd quarter. Signaturefd LLC now owns 3,364 shares of the company’s stock valued at $34,000 after acquiring an additional 1,681 shares during the period. Institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.